

December 2019

Medical drug benefit *Clinical Criteria* updates

On September 19, 2019, the Pharmacy and Therapeutics (P&T) Committee approved the following *Clinical Criteria* applicable to the **medical drug benefit** for Anthem Blue Cross and Blue Shield. These policies were developed, revised or reviewed to support clinical coding edits.

Visit [Clinical Criteria](#) to search for specific policies. For questions or additional information, use this [email](#).

Please see the explanation/definition for each category of *Clinical Criteria* below:

- New: newly published criteria
- Revised: addition or removal of medical necessity requirements, new document number
- Annual Review: minor wording and formatting updates, new document number
- Updates marked with an asterisk (*): Criteria may be perceived as more restrictive

Please share this notice with other members of your practice and office staff.

Please note: The *Clinical Criteria* listed below applies only to the medical drug benefits contained within the member's medical plan. This does not apply to pharmacy services.

Effective date	Document number	<i>Clinical Criteria</i> title	New, revised, annual review
January 15, 2020	ING-CC-0081	<i>Crysvita (burosumab-twza)</i>	Revised
January 15, 2020	ING-CC-0018	<i>Lumizyme (alglucosidase alfa)</i>	Reviewed
January 15, 2020	ING-CC-0021	<i>Fabrazyme (agalsidase beta)</i>	Revised
January 15, 2020	ING-CC-0002	<i>Zinplava (bezlotoxumab)</i>	Revised
January 15, 2020	ING-CC-0017	<i>Xiaflex (collagenase clostridium histolyticum)</i>	Revised
January 15, 2020	ING-CC-0013	<i>Mepsevii (vestronidase alfa)</i>	Revised
January 15, 2020	ING-CC-0022	<i>Vimizim (elosulfase alfa)</i>	Revised
January 15, 2020	ING-CC-0023	<i>Naglazyme (galsulfase)</i>	Revised
January 15, 2020	ING-CC-0024	<i>Elaprase (idursulfase)</i>	Revised
January 15, 2020	ING-CC-0025	<i>Aldurazyme (laronidase)</i>	Revised
January 15, 2020	ING-CC-0007	<i>Synagis (palivizumab)*</i>	Revised
January 15, 2020	ING-CC-0012	<i>Brineura (cerliponase alfa)*</i>	Revised
January 15, 2020	ING-CC-0058	<i>Octreotide Agents (Sandostatin and Sandostatin LAR)</i>	Reviewed
January 15, 2020	ING-CC-0072	<i>Selective Vascular Endothelial Growth Factor (VEGF) Antagonists*</i>	Revised

www.anthem.com/inmedicaidoc

Anthem Blue Cross and Blue Shield is the trade name of Anthem Insurance Companies, Inc., independent licensee of the Blue Cross and Blue Shield Association. Anthem is a registered trademark of Anthem Insurance Companies, Inc.

Providers who are contracted with Anthem Blue Cross and Blue Shield to serve Hoosier Healthwise, Healthy Indiana Plan and Hoosier Care Connect through an accountable care organization (ACO), participating medical group (PMG) or Independent Physician Association (IPA) are to follow guidelines and practices of the group. This includes but is not limited to authorization, covered benefits and services, and claims submittal. If you have questions, please contact your group administrator or your Anthem network representative.

IngenioRx, Inc. is an independent company providing pharmacy benefit management services on behalf of Anthem Blue Cross and Blue Shield.